BRPI0514411B8 - formulação, e, método de produzir uma formulação - Google Patents
formulação, e, método de produzir uma formulaçãoInfo
- Publication number
- BRPI0514411B8 BRPI0514411B8 BRPI0514411A BRPI0514411A BRPI0514411B8 BR PI0514411 B8 BRPI0514411 B8 BR PI0514411B8 BR PI0514411 A BRPI0514411 A BR PI0514411A BR PI0514411 A BRPI0514411 A BR PI0514411A BR PI0514411 B8 BRPI0514411 B8 BR PI0514411B8
- Authority
- BR
- Brazil
- Prior art keywords
- formulation
- producing
- seq
- antagonist
- lyophilized formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2006—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/545—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
Abstract
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60213704P | 2004-08-17 | 2004-08-17 | |
US60/602,137 | 2004-08-17 | ||
PCT/US2005/029428 WO2006023665A2 (en) | 2004-08-17 | 2005-08-17 | Il-1 antagonist formulations |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0514411A BRPI0514411A (pt) | 2008-06-10 |
BRPI0514411B1 BRPI0514411B1 (pt) | 2020-09-15 |
BRPI0514411B8 true BRPI0514411B8 (pt) | 2021-05-25 |
Family
ID=35968186
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0514411A BRPI0514411B8 (pt) | 2004-08-17 | 2005-08-17 | formulação, e, método de produzir uma formulação |
Country Status (15)
Country | Link |
---|---|
US (1) | US7365165B2 (pt) |
EP (2) | EP1778723B1 (pt) |
JP (2) | JP4948410B2 (pt) |
CN (1) | CN101014617B (pt) |
AU (1) | AU2005277357B2 (pt) |
BR (1) | BRPI0514411B8 (pt) |
CA (1) | CA2576519C (pt) |
DK (1) | DK1778723T3 (pt) |
ES (1) | ES2395035T3 (pt) |
HK (1) | HK1105421A1 (pt) |
PL (1) | PL1778723T3 (pt) |
PT (1) | PT1778723E (pt) |
SI (1) | SI1778723T1 (pt) |
WO (1) | WO2006023665A2 (pt) |
ZA (1) | ZA200701529B (pt) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2264065B1 (en) | 2003-08-05 | 2017-03-08 | Novo Nordisk A/S | Novel insulin derivatives |
ES2371361T3 (es) | 2005-12-28 | 2011-12-30 | Novo Nordisk A/S | Composiciones que comprenden una insulina acilada y zinc y método de producción de dichas composiciones. |
US7879805B2 (en) * | 2007-06-01 | 2011-02-01 | Acologix, Inc. | High temperature stable peptide formulation |
ES2744384T3 (es) | 2007-06-13 | 2020-02-24 | Novo Nordisk As | Formulación farmacéutica que comprende un derivado de insulina |
PE20091174A1 (es) * | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
US9492375B2 (en) | 2008-07-23 | 2016-11-15 | Warsaw Orthopedic, Inc. | Foam carrier for bone grafting |
RU2540922C2 (ru) | 2008-10-30 | 2015-02-10 | Ново Нордиск А/С | Лечение сахарного диабета с использованием инъекций инсулина с частотой менее одного раза в день |
NZ605928A (en) | 2010-07-29 | 2015-02-27 | Eleven Biotherapeutics Inc | Chimeric il-1 receptor type i agonists and antagonists |
BR112013010345A2 (pt) | 2010-10-27 | 2017-07-25 | Novo Nordisk As | tratamento de diabetes melitus usando as injeções de insulina administradas com intervalos de variação da injeção |
EP2790681B9 (en) | 2011-11-18 | 2023-07-26 | Regeneron Pharmaceuticals, Inc. | Method of manufacturing an extended release pharmaceutical formulation comprising polymer coated protein microparticles using spray-drying |
ES2828656T3 (es) | 2012-04-04 | 2021-05-27 | Polaris Group | Composición que comprende arginina desiminasa pegilada |
WO2014035361A1 (en) * | 2012-08-26 | 2014-03-06 | R-PHARM, CJSC (Closed Joint Stock Company) | IL-1β INHIBITOR COMPOSITION AND USE THEREOF |
JP6450364B2 (ja) | 2013-03-13 | 2019-01-09 | セセン バイオ, インコーポレイテッド | 眼送達のためのキメラサイトカイン製剤 |
US10137172B2 (en) | 2013-04-30 | 2018-11-27 | Novo Nordisk A/S | Administration regime |
US20190216925A1 (en) | 2016-09-16 | 2019-07-18 | Leukocare Ag | A Novel Method for Stabilization of a Biopharmaceutical Drug Product During Processing |
US10335464B1 (en) | 2018-06-26 | 2019-07-02 | Novo Nordisk A/S | Device for titrating basal insulin |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993000807A1 (en) * | 1991-07-03 | 1993-01-21 | Cryolife, Inc. | Method for stabilization of biomaterials |
JP3822383B2 (ja) * | 1993-12-17 | 2006-09-20 | 持田製薬株式会社 | 可溶性トロンボモジュリン含有組成物 |
JP2000510813A (ja) * | 1995-02-06 | 2000-08-22 | ジェネテイックス・インスティテュート・インコーポレイテッド | Il−12用処方 |
US5763401A (en) * | 1996-07-12 | 1998-06-09 | Bayer Corporation | Stabilized albumin-free recombinant factor VIII preparation having a low sugar content |
JP4172842B2 (ja) * | 1997-05-02 | 2008-10-29 | 生化学工業株式会社 | コンドロイチナーゼ組成物 |
US6436897B2 (en) | 1998-06-01 | 2002-08-20 | Celtrix Pharmaceuticals, Inc. | Pharmaceutical formulations for IGF/IGFBP |
US6927044B2 (en) | 1998-09-25 | 2005-08-09 | Regeneron Pharmaceuticals, Inc. | IL-1 receptor based cytokine traps |
US6472179B2 (en) * | 1998-09-25 | 2002-10-29 | Regeneron Pharmaceuticals, Inc. | Receptor based antagonists and methods of making and using |
MXPA04000747A (es) * | 2001-07-25 | 2004-07-08 | Protein Desing Labs Inc | Formulacion farmaceutica liofilizada estable de anticuerpos igg. |
DE10204792A1 (de) * | 2002-02-06 | 2003-08-14 | Merck Patent Gmbh | Lyophilisierte Zubereitung enthaltend Immuncytokine |
WO2004062646A1 (en) * | 2003-01-08 | 2004-07-29 | Chiron Corporation | Stabilized lyophilized compositions comprising tissue factor pathway inhibitor or tissue factor pathway inhibitor variants |
-
2005
- 2005-08-17 JP JP2007528019A patent/JP4948410B2/ja not_active Expired - Fee Related
- 2005-08-17 EP EP05789252A patent/EP1778723B1/en active Active
- 2005-08-17 PT PT57892523T patent/PT1778723E/pt unknown
- 2005-08-17 CA CA2576519A patent/CA2576519C/en not_active Expired - Fee Related
- 2005-08-17 BR BRPI0514411A patent/BRPI0514411B8/pt not_active IP Right Cessation
- 2005-08-17 CN CN2005800281894A patent/CN101014617B/zh active Active
- 2005-08-17 DK DK05789252.3T patent/DK1778723T3/da active
- 2005-08-17 US US11/205,935 patent/US7365165B2/en active Active
- 2005-08-17 ES ES05789252T patent/ES2395035T3/es active Active
- 2005-08-17 WO PCT/US2005/029428 patent/WO2006023665A2/en active Application Filing
- 2005-08-17 PL PL05789252T patent/PL1778723T3/pl unknown
- 2005-08-17 SI SI200531654T patent/SI1778723T1/sl unknown
- 2005-08-17 EP EP10010576A patent/EP2311871A3/en not_active Withdrawn
- 2005-08-17 AU AU2005277357A patent/AU2005277357B2/en not_active Ceased
-
2007
- 2007-02-21 ZA ZA2007/01529A patent/ZA200701529B/en unknown
- 2007-10-04 HK HK07110745.0A patent/HK1105421A1/xx not_active IP Right Cessation
-
2012
- 2012-01-26 JP JP2012013973A patent/JP2012121894A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CA2576519C (en) | 2013-05-21 |
US20060040852A1 (en) | 2006-02-23 |
JP4948410B2 (ja) | 2012-06-06 |
JP2012121894A (ja) | 2012-06-28 |
WO2006023665A3 (en) | 2006-08-03 |
BRPI0514411B1 (pt) | 2020-09-15 |
AU2005277357A1 (en) | 2006-03-02 |
SI1778723T1 (sl) | 2013-02-28 |
CA2576519A1 (en) | 2006-03-02 |
PL1778723T3 (pl) | 2013-03-29 |
US7365165B2 (en) | 2008-04-29 |
BRPI0514411A (pt) | 2008-06-10 |
EP1778723B1 (en) | 2012-11-14 |
EP1778723A2 (en) | 2007-05-02 |
DK1778723T3 (da) | 2012-12-03 |
CN101014617A (zh) | 2007-08-08 |
EP2311871A3 (en) | 2012-08-08 |
PT1778723E (pt) | 2013-01-25 |
CN101014617B (zh) | 2011-03-30 |
HK1105421A1 (en) | 2008-02-15 |
AU2005277357B2 (en) | 2011-08-04 |
ES2395035T3 (es) | 2013-02-07 |
JP2008510716A (ja) | 2008-04-10 |
EP2311871A2 (en) | 2011-04-20 |
WO2006023665A2 (en) | 2006-03-02 |
ZA200701529B (en) | 2008-09-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0514411B8 (pt) | formulação, e, método de produzir uma formulação | |
CY1119243T1 (el) | Φαρμακοτεχνικες μορφες ανταγωνιστη του vegf | |
BR0208183A (pt) | Peptìdeo modificado por wt1 | |
RS50966B (sr) | Agonisti pyy i njihova upotreba | |
WO2006105112A3 (en) | Amino acid-containing composition for preventing or remedying in the skeletal muscle of aged people | |
RS51213B (sr) | Farmaceutski vaginalni gel koji sadrži tenofovir | |
BR0208207A (pt) | Redução da imunogenicidade das proteìnas de fusão | |
ATE410178T1 (de) | Oligopeptide zur verringerung erhöhter blutharnstoffkonzentration | |
ATE470443T1 (de) | Indol-1-yl-essigsäurederivate | |
ECSP034438A (es) | Nuevos peptidos como inhibidores de ns-3-serina proteasa del virus de la hepatitis c | |
AR113422A2 (es) | Agentes tensioactivos reconstituidos que tienen propiedades mejoradas | |
NO20054440L (no) | Flytende formuleringer av tumornekrosefaktorbindende proteiner | |
BRPI0519070A2 (pt) | composiÇço de fator de crescimento de queratinàcito liofilizada, mÉtodos para preparar um fator de crescimento de queratinàcito liofilizado, e para tratar uma doenÇa, e, kit para preparar uma composiÇço farmacÊutica aquosa | |
BR9811094A (pt) | Agente terapêutico para tumores linfáticos | |
BRPI0417938A (pt) | formulações de proteìnas hidrofóbicas em uma composição imunogênica que possui tolerabilidade aperfeiçoada | |
BR112017017609A2 (pt) | proteína de fusão fc, e, composição farmacêutica. | |
BR0009472A (pt) | Antagonistas de lhrh com propriedades desolubilidade aperfeiçoadas | |
ATE252375T1 (de) | Bioabbaubare mikropartikeln mit verzögerter wirkstofffreisetzung | |
BRPI0415277A (pt) | célula, vetor, método para produzir proteìna gama-carboxilada, proteìna gama-carboxilada isolada, uso da mesma, método para produzir uma composição farmacêutica, composição farmacêutica, método para produzir fator x de humano gama-carboxilado, uso de fator x isolado, método para produzir protrombina de humano gama-carboxilada, uso de protrombina isolada, e, método para promover coagulação aumentada ou diminuìda em um indivìduo | |
CY1105019T1 (el) | Υποκατεστημενες c-ιμιδαζο-[1,2-α]πυριδιν-3-υλο-μεθυλαμινες | |
ATE337355T1 (de) | Sulfoniertes polyetherketonketon | |
DE60102147D1 (de) | Anti-gefrier proteine, deren herstellung und verwendung | |
WO2002058589A3 (en) | Agents and methods for promoting bone growth | |
HUP0401732A2 (hu) | Kopolimerek használata aktív szerként peptidet és fehérjét tartalmazó galenikus formák előállításához | |
DK1268522T3 (da) | LH-RH-antagonister samt fremstilling deraf og anvendelse deraf som lægemidler |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 15/09/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/08/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 18A ANUIDADE. |
|
B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2736 DE 13-06-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |